Verona Pharma (NASDAQ:VRNA) has randomized
the last patient in its Phase 2b dose-ranging study evaluating the
effect of nebulized ensifentrine as an add-on to treatment with a long
acting bronchodilator in patients with moderate-to-severe chronic
obstructive pulmonary disease (“COPD”).
Top-line data are expected around year end.
Preparations are underway for End-of-Phase 2 meeting with the FDA expected in 1H 2020.
Commencement of Phase 3 trials are expected in 2020.
The trial enrolled a total of 416 patients. The
primary endpoint is improvement in lung function with ensifentrine after
four weeks of treatment.
https://seekingalpha.com/news/3506454-verona-pharma-completes-enrollment-mid-stage-nebulized-ensifentrine-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.